Low Body Mass Index as a Significant Risk Factor for Hypoglycemia in Hospitalized Elderly Patients With Acute

Satoru Sekiguchi1, Ryuichi Ohta2, Chiaki Sano3

  • 1Family Medicine, Shimane University Faculty of Medicine, Izumo, JPN.

Cureus
|December 2, 2024
PubMed

Insights

Lower body mass index (BMI) is a key risk factor for hypoglycemia in elderly patients hospitalized with acute pyelonephritis. Identifying and managing low BMI can reduce hypoglycemia events and improve outcomes in this population.

Area of Science:

  • Geriatric Medicine
  • Internal Medicine
  • Clinical Research

Background:

  • Hypoglycemia is a serious concern in elderly patients hospitalized with acute illnesses like pyelonephritis.
  • It is linked to increased morbidity and mortality, necessitating identification of specific risk factors.

Purpose of the Study:

  • To determine the risk factors for hypoglycemic events in elderly patients admitted with acute pyelonephritis.

Main Methods:

  • Retrospective cohort study of 294 elderly patients (≥65 years) hospitalized with acute pyelonephritis.
  • Data collected included demographics, comorbidities, and clinical outcomes.
  • Multivariate logistic regression identified independent risk factors for hypoglycemia (blood glucose < 70 mg/dL).

Main Results:

  • Hypoglycemia occurred in 49.7% of patients.
  • Lower body mass index (BMI) was a significant independent risk factor (OR = 0.84, p < 0.00001).
  • Age, sex, and common comorbidities did not significantly predict hypoglycemia risk. Hypoglycemic patients had higher in-hospital mortality (46.6% vs. 31.1%).

Conclusions:

  • Lower BMI is an independent risk factor for hypoglycemia in elderly patients with acute pyelonephritis.
  • Early identification and management of low BMI are crucial for reducing hypoglycemia and improving outcomes in this vulnerable group.

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
152
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
504
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
145
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
93
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
172
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
139